MSF Access

Drawing on MSF’s frontline experience across emergencies, we’re calling on EU to progress towards a system that ensures fair and equitable benefit‑sharing in exchange for access to pathogens and genetic resources used in R&D, including clinical trials. msfaccess.org/msf-calls-eu-u…

We hope positive elements of the intellectual property in the EU-India trade deal serve as a template, enabling other countries to resist pressure during trade negotiations and safeguard access to affordable medicines,” added Sarathy Rajendran, Executive Director, MSF South Asia.

“We call on Government of India to ensure careful implementation of the enforcement and trade secret provisions which will be crucial to maintaining these hard-earned gains,” warned Roshan Joseph, Legal and Policy Advisor, MSF Access.

In 2011, around 3000 people marched in India to oppose proposed harmful provisions in EU–India trade deal that threatened access to affordable medicines. Fifteen years later, after two decades of sustained advocacy, those were excluded from the final deal. youtube.com/watch?v=VOWMYy…

👎Some provisions may impact generic competition and hence require careful consideration. Read our full reaction: msfaccess.org/dnp-and-msf-we…

India-EU free trade agreement full text has been released and the intellectual property chapter: 👍Largely preserves India’s public health safeguards and doesn't go beyond @wto TRIPS agreement 🛑 BUT 🛑

From outbreaks to pandemics, MSF has repeatedly seen patients and communities, who contribute vital samples, data and clinical participation to lifesaving innovations, being denied access to the very products they help make possible. PABS system must guarantee access for all.

Read MSF’s recommendations for a strong WHO Pathogen Access and Benefit-Sharing (PABS) system calling for reliable, equitable and accountable access to vaccines, diagnostics and treatments developed from shared samples and data. msfaccess.org/ensuring-colle…

Weakening safeguards for research participants sends a dangerous global signal — especially as countries negotiate at the WHO on an agreement on research and access during health emergencies.

MSF has already warned that this law marks a serious rollback of protections for people who volunteer in clinical trials and has urged the Brazilian government to reverse course msfaccess.org/msf-denounces-…

👉@MSF_brasil is seeking to intervene in a Supreme Court case challenging Brazil’s new law on research, which limits the right of clinical trial participants to receive free access to medicines developed from the studies they joined.

Vaccines: Most un- and under-vaccinated children live in fragile, conflict-affected contexts, where systemic barriers keep vaccination coverage low. Governments, donors and health actors must ramp up immunisation in these settings and ensure funding gaps do not compromise equity.

NCDs: The UN political declaration is promising, but diabetes targets are missing. Now, access to lifesaving tools like insulin pens, glucose monitoring tools & antipsychotics must be ensured and added to the Essential Medicines List.

MSF representatives addressed critical issues in fragile settings at the @WHO Executive Board #EB158 this week, calling for urgent action on: 🔹Antimicrobial resistance (AMR) 🔹Mental health 🔹Noncommunicable diseases (NCDs) 🔹Vaccines Read the statements: msfaccess.org/msf-statements…

...and the harmful consequences of the Trump administration’s drive to reshape US foreign assistance have only just started to unfold.

Great read: an MSF reflection on antimicrobial evidence gaps and implementation needs in humanitarian settings, grounded in MSF's work in fragile contexts. journals.plos.org/globalpubliche…

Why is #insulin, an essential and lifesaving medication that’s existed for over 100 years, still priced, patented, and distributed like a 💎luxury good💎? Listen as our advocacy advisor, Candice Sehoma, unpacks it on this #podcast episode: open.spotify.com/episode/6p39lQ…